Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Retained Earnings (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Retained Earnings for 11 consecutive years, with -$2.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 428214.71% to -$2.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.6 billion, a 428214.71% decrease, with the full-year FY2025 number at -$2.6 billion, down 428214.71% from a year prior.
  • Retained Earnings was -$2.6 billion for Q4 2025 at Intellia Therapeutics, down from $990000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $3.3 million in Q3 2024 to a low of -$2.6 billion in Q4 2025.
  • A 5-year average of -$562.1 million and a median of -$8.4 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: plummeted 70300200.0% in 2021, then surged 156.54% in 2025.
  • Intellia Therapeutics' Retained Earnings stood at -$703.0 million in 2021, then surged by 98.94% to -$7.5 million in 2022, then surged by 69.74% to -$2.3 million in 2023, then skyrocketed by 126.79% to $605000.0 in 2024, then crashed by 428214.71% to -$2.6 billion in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Retained Earnings are -$2.6 billion (Q4 2025), $990000.0 (Q3 2025), and $653000.0 (Q2 2025).